Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 56,794 $ 24,869
Marketable securities 119,438 166,076
Accrued interest receivable 377 687
Prepaid research and development expenses 7,922 9,910
Other prepaid expenses 1,418 1,381
Total current assets 185,949 202,923
Property and equipment, net 2,242 2,409
Operating lease right-of-use asset 249 235
Other assets 160 160
Total assets 188,600 205,727
Current liabilities:    
Accounts payable 1,213 2,503
Accrued research and development expenses 7,351 9,218
Accrued restructuring 1,717 3,193
Other accrued liabilities 1,641 2,722
Total current liabilities 11,922 17,636
Long-term portion of operating lease liability 1,630 1,743
Total liabilities 13,552 19,379
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 100,000,000 shares authorized; 68,882,459 and 68,882,459 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively 7 7
Additional paid-in capital 814,131 812,133
Accumulated other comprehensive (loss) income (130) 80
Accumulated deficit (638,960) (625,872)
Total stockholders' equity 175,048 186,348
Total liabilities and stockholders' equity $ 188,600 $ 205,727